Compare Meta Platforms Inc (META) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Sanofi SA — how do they compare? Meta Platforms Inc trades at $640.51 (market cap $1.64T), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Meta Platforms Inc is far larger — about 15.6× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| META | SNY | |
|---|---|---|
Market Cap | $1.64T | $104.83B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $52.34 |
52-Week Low | $525.72 | $41.33 |
Enterprise Value | $1.65T | $121.32B |
Dividend Yield | 0.33% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $643.81, down 0.34% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with 2025 revenue of $201B, net income of $60.5B, and impressive profitability margins including 81.9% gross margin and 32.8% net margin. Recent catalysts include the launch of Muse Spark AI model and consistent earnings beats, with Q1 2026 EPS of $10.44 significantly exceeding expectations of $6.70.
The outlook remains positive with analyst consensus price target of $817.32 representing 27% upside potential. Key opportunities include AI monetization through Muse Spark and strong advertising revenue growth, while risks involve ongoing litigation regarding youth addiction claims and elevated capital expenditures for AI infrastructure. Wall Street maintains strong bullish sentiment with 79% buy ratings.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
